Seoul National University Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (15)

2024

  1. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

    Lung Cancer, Vol. 197

  2. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

    Advances in Therapy, Vol. 41, Núm. 11, pp. 4125-4139

  3. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

2023

  1. Robotic versus laparoscopic liver resection for huge (≥10 cm) liver tumors: an international multicenter propensity-score matched cohort study of 799 cases

    HEPATOBILIARY SURGERY AND NUTRITION, Vol. 12, Núm. 2, pp. 205-216

  2. Robotic versus laparoscopic liver resection for huge (≥10 cm) liver tumors: an international multicenter propensity-score matched cohort study of 799 cases

    HEPATOBILIARY SURGERY AND NUTRITION, Vol. 12, Núm. 2, pp. 205-216

2022

  1. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

  2. Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease

    Nature Reviews Neurology, Vol. 18, Núm. 4, pp. 203-220

2021

  1. Pressure injury prediction models for critically-ill patients should consider both the case-mix and local factors

    Intensive and Critical Care Nursing

  2. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

    Journal of Clinical Oncology, Vol. 39, Núm. 27, pp. 2991-3001

2020

  1. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the KEYNOTE-010 study

    Journal of Clinical Oncology, Vol. 38, Núm. 14, pp. 1580-1591

2017

  1. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502

2016

  1. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

    The Lancet Haematology, Vol. 3, Núm. 11, pp. e506-e515

  2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial

    The Lancet, Vol. 387, Núm. 10027, pp. 1540-1550

2015

  1. Panobinostat: A novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

    Expert Review of Anticancer Therapy, Vol. 15, Núm. 7, pp. 737-748

2014

  1. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206